Lifecore Biomedical Inc Stock Price, News & Analysis

Lifecore Biomedical (NASDAQ: LFCR) has been selected by Humanetics to provide CDMO services for the development of BIO 300, a novel radioprotective agent. The collaboration focuses on preventing acute radiation syndrome, with development funded by the Department of Defense.

Under the agreement, Lifecore will handle technology transfer of the fill and finish process for BIO 300, including formulation development, gap assessment, and pilot batch filling. The company will also conduct analytical method work and feasibility assessments for future development.

BIO 300 is currently in late-stage clinical development for multiple applications, including:

• Mitigation of impaired pulmonary function in COVID-19 patients
• Protection of cancer patients from radiation therapy side effects
• Prevention of acute radiation syndrome for warfighters, First Responders, and civilians

The project is supported by a $5,132,520 award from the Department of Defense's Peer Reviewed Medical Research Program.

Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in three major upcoming conferences in March 2025.

The company will participate in the TD Cowen 45th Annual Health Care Conference in Boston (March 3-5), where CEO Paul Josephs will deliver a corporate presentation on March 4. Additionally, Lifecore will attend the KeyBanc Capital Markets Healthcare Forum (March 18-19) virtually, featuring a fireside chat with Mr. Josephs on March 19.

The company will also participate in DCAT Week 2025 in New York (March 17-20), engaging with current and prospective customers. A live webcast of the TD Cowen presentation will be available on Lifecore's investor website, with a replay accessible post-conference.

Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the 2025 BIO CEO & Investor Conference. The event will be held on February 10-11, 2025, in New York, NY.

The company's management team, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will engage in one-on-one meetings during the conference. This participation demonstrates Lifecore's commitment to investor relations and market engagement.

Lifecore Biomedical (NASDAQ: LFCR) has announced a special stockholder meeting scheduled for April 10, 2025, to vote on removing the Convertible Preferred Stock Exchange Cap. This cap currently limits the conversion of Series A Preferred Stock to 19.99% of outstanding common stock prior to the issuance.

The proposal, if approved, would allow for potential conversion of Convertible Preferred Stock into a maximum of 6,056,284 shares of common stock based on the current conversion price. The meeting aligns with the terms of the January 9, 2023 Purchase Agreement. Stockholders of record as of February 18, 2025, will be eligible to vote.

The company emphasized that no holders have yet converted their preferred shares to common stock, and Lifecore currently has no plans to raise additional equity capital. A preliminary proxy statement will be filed with the SEC, followed by a definitive proxy statement with detailed meeting information.

Lifecore Biomedical (NASDAQ: LFCR) has announced the sale of its unused 10-head isolator filler for $17 million to a non-competitive buyer. The company received $7 million upfront, with the remaining amount to be paid in three installments over the next 18 months.

This strategic move follows the recent installation of a high-speed 5-head filler, which has doubled the company's available capacity. The new equipment supports up to $300 million in annual revenue, sufficient for Lifecore's mid-term and long-term growth objectives. The company is currently engaging with customers to utilize the new 5-head filler's speed and aseptic isolation capabilities.

Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take place from January 13-16, 2025, in San Francisco, California.

The company's management team, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will be conducting one-on-one meetings during the conference. This participation represents an important opportunity for Lifecore to engage with healthcare industry stakeholders and investors.

Lifecore Biomedical (NASDAQ: LFCR) reported Q2 fiscal 2025 results with revenues of $32.6 million, up 8% year-over-year. The company recorded a net loss of $6.6 million ($0.25 per share) compared to net income of $14.2 million in the prior year period. Adjusted EBITDA increased to $6.5 million from $5.4 million.

Key developments include signing two new project agreements, completing installation of a high-speed multi-purpose 5-head isolator filler that doubles capacity, and strengthening the balance sheet through a $24.3 million private placement and favorable restructuring of the BMO credit facility. Gross profit improved to $11.1 million, while operating expenses increased primarily due to higher stock-based compensation and professional fees.

The company regained Nasdaq compliance and made several key leadership appointments, including a new CFO and executives in operations, HR, and quality services.

Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has scheduled its second quarter fiscal 2025 financial results announcement for January 2, 2025, after market close. The company's senior management will host a webcast at 4:30 p.m. Eastern Time to discuss the quarterly results and recent corporate developments. The webcast will be accessible through Lifecore's investor relations website, with a replay available for at least 14 days following the live presentation.

Lifecore Biomedical (NASDAQ: LFCR) has been selected by Nirsum Laboratories to provide CDMO services for their lead candidate NRS-033, a novel treatment for opioid and alcohol use disorders entering Phase 2 clinical development.

The agreement encompasses assessment and technology transfer of fill and finish processes for NRS-033, leveraging Lifecore's expertise in sterile injectable pharmaceuticals. Lifecore will provide filled syringes for clinical development, with potential to create a comprehensive development and commercialization plan for the entire fill and finish process.